NCT05453396View on ClinicalTrials.gov

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

December 15, 2026

Study Completion Date

July 6, 2027

Conditions
Post-Transplant Lymphoproliferative DisorderRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Neoplastic Post-Transplant Lymphoproliferative DisorderRefractory B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Mantle Cell LymphomaRefractory Neoplastic Post-Transplant Lymphoproliferative Disorder
Interventions
BIOLOGICAL

Loncastuximab Tesirine

Given IV

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

University of Washington

OTHER